Date: 2017-05-25
Type of
information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: Adaptimmune (UK)
Product: NY-ESO SPEAR T-cells targeting NY-ESO in combination with Keytruda® (pembrolizumab)
Action
mechanism:
- cell therapy/gene therapy/immunotherapy product/monoclonal antibody/immune checkpoint inhibitor. Keytruda® (pembrolizumab - MK-3475) is an highly selective monoclonal anti-PD-1 antibody designed to restore the natural ability of the immune system to recognize and target cancer cells by selectively achieving dual ligand blockade (PD-L1 and PD-L2) of the PD-1 protein. By blocking PD-1, pembrolizumab enables activation of the immune system’s T-cells that target cancer by essentially releasing a brake on the immune system.
Disease: relapsed and/or refractory multiple myeloma
Therapeutic
area: Cancer - Oncology
Country: USA
Trial
details:
- This study is intended for men and women at least 18 years of age who have relapsed and/or refractory multiple myeloma. This 2-arm randomized pilot study will test the safety, tolerability and efficacy of NY-ESO-1?²??T alone (Arm 1) or in combination with pembrolizumab (Arm 2) in subjects who have the appropriate HLA-A2 marker, and whose bone marrow expresses the NY-ESO-1 and/or LAGE-1a protein.
- This study will take a subject's T cells and give them a T cell receptor protein that recognizes and attacks the tumors. (NCT03168438)
Latest
news:
- • On May 25, 2017, Adaptimmune Therapeutics announced that it has initiated its study of NY-ESO SPEAR T-cells targeting NY-ESO in combination with Keytruda® (pembrolizumab). This study is now open for enrollment. This open-label, randomized pilot study will evaluate the safety and anti-tumor activity of NY-ESO therapeutic candidate alone or in combination with pembrolizumab in patients who are HLA-A*02 positive and have relapsed and refractory multiple myeloma expressing NY-ESO-1 and/or LAGE-1a. The study will enroll up to 20 patients.
Is
general: Yes
